Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.69 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.53 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.53 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29411617 | 1.00 | MEN1 (0.69) | MEN1KMT2ASMN1; SMN2ALDH1A1CYP3A4 | |
| SCHEMBL29411394 | 0.91 | KMT2A (0.57) | MEN1KMT2ASMN1; SMN2ALDH1A1CYP3A4 | |
| SCHEMBL21045155 | 0.91 | KMT2A (0.57) | MEN1KMT2ASMN1; SMN2ALDH1A1CYP3A4 | |
| SCHEMBL21045264 | 0.89 | SMN1; SMN2 (0.71) | MEN1KMT2ASMN1; SMN2ALDH1A1CYP3A4 | |
| SCHEMBL29411562 | 0.89 | SMN1; SMN2 (0.71) | MEN1KMT2ASMN1; SMN2ALDH1A1CYP3A4 | |
| SCHEMBL21045344 | 0.88 | MEN1 (0.53) | MEN1KMT2ASMN1; SMN2ALDH1A1CYP3A4 | |
| SCHEMBL29411441 | 0.88 | MEN1 (0.53) | MEN1KMT2ASMN1; SMN2ALDH1A1CYP3A4 | |
| SCHEMBL21045092 | 0.88 | HDAC3 (0.54) | MEN1KMT2ASMN1; SMN2ALDH1A1CYP3A4 | |
| SCHEMBL30920079 | 0.87 | TSHR (0.77) | MEN1KMT2ASMN1; SMN2ALDH1A1CYP3A4 | |
| SCHEMBL21227017 | 0.87 | TSHR (0.77) | MEN1KMT2ASMN1; SMN2ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240182419-A1 | ANTI-CANCER COMPOUNDS | THE UNIVERSITY OF SYDNEY (AU) | 2024-06-06 | — | — | US | disclosed |
| US-11939296-B2 | Anti-cancer compounds | THE UNIVERSITY OF SYDNEY (AU) | 2024-03-26 | — | — | US | disclosed |
| US-20230028660-A1 | ANTI-CANCER COMPOUNDS | THE UNIVERSITY OF SYDNEY (AU) | 2023-01-26 | — | — | US | disclosed |
| US-20230028660-A1 | ANTI-CANCER COMPOUNDS | THE UNIVERSITY OF SYDNEY (AU) | 2023-01-26 | — | — | US | disclosed |
| US-11472774-B2 | Anti-cancer compounds | THE UNIVERSITY OF SYDNEY (AU) | 2022-10-18 | — | — | US | disclosed |
| US-20220089539-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE INC. (TW) | 2022-03-24 | — | — | US | disclosed |
| US-11040945-B2 | Tubulin inhibitors | LIN BIOSCIENCE PTY LTD. | 2021-06-22 | — | — | US | disclosed |
| US-11040945-B2 | Tubulin inhibitors | LIN BIOSCIENCE PTY LTD. | 2021-06-22 | — | — | US | disclosed |
| US-20210094915-A1 | ANTI-CANCER COMPOUNDS | THE UNIVERSITY OF SYDNEY (AU) | 2021-04-01 | — | — | US | disclosed |
| US-20210094915-A1 | ANTI-CANCER COMPOUNDS | THE UNIVERSITY OF SYDNEY (AU) | 2021-04-01 | — | — | US | disclosed |
| EP-3746422-A1 | ANTI-CANCER COMPOUNDS | The University Of Sydney (AU) | 2020-12-09 | — | — | EP | disclosed |
| WO-2019148244-A1 | ANTI-CANCER COMPOUNDS | THE UNIVERSITY OF SYDNEY (AU) | 2019-08-08 | — | — | WO | disclosed |
| WO-2019148244-A1 | ANTI-CANCER COMPOUNDS | THE UNIVERSITY OF SYDNEY (AU) | 2019-08-08 | — | — | WO | disclosed |
| WO-2019113242-A1 | TUBULIN INHIBITORS | Lin BioScience, LLC (US) | 2019-06-13 | — | — | WO | disclosed |
| US-20190169127-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE INC. (TW) | 2019-06-06 | — | — | US | disclosed |
| US-20190169127-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE INC. (TW) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11472774-B2 | Anti-cancer compounds | MKI67, CDKN1A, TP53 | MEN1 244/4885KMT2A 975/4885SMN1; SMN2 530/4885 |
| US-11939296-B2 | Anti-cancer compounds | MKI67, TP53, CDK5 | MEN1 467/4885KMT2A 1315/4885SMN1; SMN2 1105/4885 |
| US-20220089539-A1 | TUBULIN INHIBITORS | TUBB3, TUBB1, TUBB | MEN1 955/4885KMT2A 2339/4885SMN1; SMN2 1062/4885 |
| US-20230028660-A1 | ANTI-CANCER COMPOUNDS | MKI67, TP53, CDK5 | MEN1 467/4885KMT2A 1315/4885SMN1; SMN2 1105/4885 |
| US-11040945-B2 | Tubulin inhibitors | TUBB3, TUBB1, TUBB | MEN1 955/4885KMT2A 2339/4885SMN1; SMN2 1062/4885 |
| US-20240182419-A1 | ANTI-CANCER COMPOUNDS | MKI67, TP53, CDK5 | MEN1 467/4885KMT2A 1315/4885SMN1; SMN2 1105/4885 |
| US-20190169127-A1 | TUBULIN INHIBITORS | TUBB3, TUBB1, TUBB | MEN1 955/4885KMT2A 2339/4885SMN1; SMN2 1062/4885 |
| US-20210094915-A1 | ANTI-CANCER COMPOUNDS | MKI67, TP53, CDK5 | MEN1 467/4885KMT2A 1315/4885SMN1; SMN2 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.